Capricor Therapeutics | CAPR - Gross Profit On Sales

Stock Price
34.20
Daily Change
-0.52 -1.50%
Monthly
11.91%
Yearly
254.77%
Q2 Forecast
30.35

Capricor Therapeutics reported 11.13M in Gross Profit on Sales for its fiscal quarter ending in December of 2024.





Gross Profit On Sales Change Date
Bioline Rx USD 343K 111K Sep/2025
Capricor Therapeutics 11.13M 8.87M Dec/2024
Cipla INR 41.64B 6.31B Dec/2025
Cytokinetics USD 17.76M 15.82M Dec/2025
Geron USD 46.71M 525K Dec/2025
Grifols EUR 766.49M 39.74M Dec/2024
Immunic 0 0 Mar/2025
J&J USD 16.6B 118M Dec/2025
Plus Therapeutics 1.37M 30K Dec/2025
Prothena USD 21K 2.39M Dec/2025
PTC Therapeutics USD 148.38M 39.31M Dec/2025
Sarepta Therapeutics USD 43.55M 204.36M Dec/2025